中医药治疗高脂血症临床试验核心结局指标集:系统评价与德尔菲调查的研究方案
本研究方案旨在为中医药治疗高脂血症的临床试验制定核心结局指标集(COS-CM-Hyperlipidemia)。方案包括四个阶段:系统评价识别潜在结局、成立研究顾问组、开展三轮德尔菲专家调查、举行共识会议确定最终条目与定义,并推广更新该COS。该COS有望改善中医药高脂血症试验的设计与实施,使其符合国际标准并提高结果可比性与实用性。
要点
- 制定中医药治疗高脂血症临床试验的核心结局指标集(COS)
- 采用系统评价、三轮德尔菲调查和共识会议四阶段方法
- 旨在提高中医药高脂血症试验结果的国际可比性与实用性
核心结论
- 该COS的制定将改善中医药治疗高脂血症试验的设计与实施,使其符合国际标准,并提高结果的可比性与实用性。
研究设计与样本
- 本方案包括四个阶段:系统评价识别潜在重要结局并成立研究顾问组形成候选结局集;邀请专家小组进行三轮德尔菲调查收集对结局重要性的意见;与临床医生、患者及其他关键利益相关者举行共识会议确定最终条目与定义;推广并更新COS-CM-Hyperlipidemia。
临床怎么用
- 该COS可用于规范中医药治疗高脂血症临床试验的结局选择,提高不同研究之间的可比性和结果实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperlipidemia, defined as elevated lipid levels, is the primary and major risk factor for atherosclerotic cardiovascular disease. Several studies have evaluated the effects of Chinese medicine (CM) on hyperlipidemia. However, due to the varied designs and methods of these studies, data synthesis has been difficult, restricting the practical value of the findings. Developing a core outcome set (COS) could solve these methodological concerns. In this paper, we report a protocol to develop a COS for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia). METHODS: The development of COS-CM-Hyperlipidemia will include four stages: (1) a systematic review to identify potential important outcomes-a study advisory group, composed of core stakeholders of hyperlipidemia, will be set up afterwards to evaluate the identified outcomes and a candidate outcome set will be developed accordingly; (2) a panel of experts will be invited to conduct a three-round Delphi survey, so that the experts' opinions on the importance of outcomes for treating hyperlipidemia with CM will be collected; (3) a consensus meeting with clinicians, patients, and other key stakeholders will be conducted to finalize the items and definitions; and (4) COS-CM-Hyperlipidemia will be promoted and updated. DISCUSSION: The development of this COS will improve the design and operation of CM trials on hyperlipidemia, keeping them in compliance with international standards, as well as the comparability and utility of their results. TRIAL REGISTRATION: The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.comet-initiative.org/studies/details/983 . Registered on 25 April 2017.
引用
- Li G, Zhou L, Ouyang W, et al. A core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey. Trials. 2019. PMID: 30612586. doi:10.1186/s13063-018-3082-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。